Global pharma supply chains deepen reliance on China and India despite vulnerability concerns

While companies pursue diversification to reduce risk, the upstream concentration of active pharmaceutical ingredients and starting materials in Asia is accelerating—not retreating—driven by cost and capacity advantages.

Pharmaceutical supply chains are becoming increasingly concentrated in China and India, not diversifying away from them. Europe sources roughly 67 percent of its active pharmaceutical ingredients (APIs) from outside the region, with China and India as dominant suppliers. The U.S. relies on even larger external proportions. While some companies attempt to diversify by sourcing from India instead of China, this strategy masks a deeper vulnerability: India itself imports 70 percent of its API and key starting material requirements from China. This creates a triangular dependency that shifting suppliers does not eliminate. The concentration is expanding beyond raw ingredients toward finished medicines. China and India are both rapidly increasing production capacity in finished pharmaceutical products, meaning Europe's historical reliance on imported APIs could evolve into dependence on finished drugs. In 2024, India and China together accounted for 88 percent of global active pharmaceutical ingredient filings with the FDA, up from nearly zero in 1981, while the U.S. share fell to 3 percent and the EU to 6 percent. Geopolitical disruptions and tariff pressures are forcing companies and governments to prioritize resilience. The pandemic exposed this vulnerability when Chinese factory shutdowns in 2020 caused India to restrict exports of 26 drugs, including paracetamol and antibiotics, due to exhausted supplies of Chinese-sourced key starting materials. Yet structural barriers persist: fermentation technology remains a technical barrier to Indian self-sufficiency, and regulatory compliance requirements make rapid supplier switching difficult. Governments are responding with strategic interventions. The EU's Critical Medicines Act assesses manufacturing scarcity and API concentration, creating prioritized risk registries. India's Production Linked Incentive scheme aims to develop domestic API capacity, though experts characterize it as a necessary but long-term solution to a structural problem. The trend toward geographic redundancy and buffer stocks reflects recognition that cost-optimization alone can no longer drive supply chain design.

How could this affect you

Traced by who's actually in the path of this — not everyone is.

Likely

If you are a patient in developed markets dependent on generic medicines

Supply disruptions in China or India could reduce availability of affordable generic drugs. India's 20 percent share of global generic medicines by volume makes interruptions in Indian supply particularly consequential; India's own 70 percent dependency on Chinese inputs means a China supply shock propagates through Indian manufacturing.

Likely

If you are a pharmaceutical company sourcing APIs from Asia

Geopolitical tensions between China and India, or between either country and the West, could disrupt supply without warning. The triangular dependency means substituting Indian suppliers for Chinese ones does not eliminate underlying exposure. Regulatory constraints on supplier switching mean companies cannot pivot quickly even if alternatives exist.

Likely

If you are a U.S. or European government planning health security

Deep structural dependence on Asian APIs and finished products creates vulnerability to coercion via export controls, tariffs, or supply restrictions. Unlike rare earths, pharmaceutical supply concentration in two countries creates asymmetric leverage: China or India could restrict supply to allies of the U.S., not just the U.S. directly, constraining allied supply chains.

Off-Lens

Who is covering this — and who is not.

6 articles · 2 countries · via GDELT

🇮🇳India

83%

🇺🇸United States

17%

🇮🇳timesofindia.indiatimes.com 🇺🇸apnews.com 🇮🇳indiatoday.in 🇮🇳news18.com 🇮🇳wionews.com 🇮🇳theprint.in

Perspectives not in sources

🇨🇳 China

Analysis

Reporting on pharma supply chain concentration is heavily weighted toward U.S. and European government and industry perspectives, with most coverage examining what Western companies and policymakers should do. Far less visible is how China frames its role—whether as a natural outcome of comparative advantage or as strategic leverage it intends to use. Indian coverage focuses on the country's vulnerability to China within its own pharma ecosystem, but less on India's own growing role in finished medicines production, which could give it leverage with countries dependent on its generics. The strategic asymmetry—that India is vulnerable to China but that Europe and the U.S. are vulnerable to India as well as China—is present in coverage but not always made explicit.

Chanakya's Move

Whose move this was, what they're betting on, what could counter it.

China and India are not pursuing supply chain dominance in pharmaceuticals through explicit strategy; rather, they are capturing and consolidating structural advantage built on decades of cost-driven globalization. China's position is particularly strong: it controls both the upstream (APIs and starting materials) and increasingly the downstream (finished products). India, despite marketing itself as 'pharmacy of the world,' is itself a choke point dependent on China—a vulnerability India's government recognizes but cannot quickly resolve. The counter-move by Western governments is not to abandon Asia but to build redundancy: stockpiling, fostering multiple suppliers, and investing in nearshoring. However, this is slow and politically contested. China's leverage lies in the credible threat that it could restrict supply to U.S. allies, not just the U.S., which would inflict broader damage than rare earth restrictions. India's counter-leverage is limited—it benefits from the current arrangement and has little incentive to accelerate APIs development if it raises costs. Western governments face a structural bind: rebuilding self-sufficiency in APIs is decades away and expensive; accepting dependence accepts risk.